Portal de investigação
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Albshesh, A
- Taylor, J
- Savarino, EV
- Truyens, M
- Armuzzi, A
- Ribaldone, DG
- Shitrit, ABG
- Fibelman, M
- Molander, P
- Liefferinckx, C
- Nancey, S
- Korani, M
- Rutka, M
- Barreiro-de Acosta, M
- Domislovic, V
- Suris, G
- Eriksson, C
- Alves, C
- Mpitouli, A
- di Jiang, C
- Tepes, K
- Coletta, M
- Foteinogiannopoulou, K
- Gisbert, JP
- Amir-Barak, H
- Attauabi, M
- Seidelin, J
- Afif, W
- Marinelli, C
- Lobaton, T
- Pugliese, D
- Maharshak, N
- Cremer, A
- Limdi, JK
- Molnár, T
- Otero-Alvarin, B
- Krznaric, Z
- Karmiris, K
- Raine, T
- Drobne, D
- Koutroubakis, I
- Chaparro, M
- Yanai, H
- Burisch, J
- Kopylov, U
Unidades de investigação
Abstract
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
Dados da publicação
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm10132914
- PubMed:
- 34209880
- Link para outro recurso:
- www.scopus.com
Journal of Clinical Medicine MDPI AG
Citações Recebidas na Web of Science: 8
Citações Recebidas na Scopus: 12
Documentos
- Não há documentos
Filiações
Keywords
- Crohn's disease; anti-TNF failure; treatment response; treatment failure; ustekinumab; vedolizumab
Projetos associados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
